GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Retained Earnings

Elanix Biotechnologies AG (FRA:ELN) Retained Earnings : €-6.80 Mil (As of Dec. 2018)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Elanix Biotechnologies AG's retained earnings for the quarter that ended in Dec. 2018 was €-6.80 Mil.

Elanix Biotechnologies AG's quarterly retained earnings declined from Dec. 2017 (€-3.07 Mil) to Jun. 2018 (€-6.56 Mil) and declined from Jun. 2018 (€-6.56 Mil) to Dec. 2018 (€-6.80 Mil).

Elanix Biotechnologies AG's annual retained earnings declined from Dec. 2016 (€-0.07 Mil) to Dec. 2017 (€-3.07 Mil) and declined from Dec. 2017 (€-3.07 Mil) to Dec. 2018 (€-6.80 Mil).


Elanix Biotechnologies AG Retained Earnings Historical Data

The historical data trend for Elanix Biotechnologies AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Retained Earnings Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -2.79 -0.07 -3.07 -6.80

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -1.75 -3.07 -6.56 -6.80

Elanix Biotechnologies AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Elanix Biotechnologies AG  (FRA:ELN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines